D2C7-CAR

D2C7-CAR is a dual-specific chimeric antigen receptor (CAR) T-cell therapy designed to target both wild-type epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII) mutation. Developed by researchers at Duke University, this cell therapy aims to address the significant intratumoral heterogeneity found in glioblastoma (GBM) and other EGFR-aberrant tumors like medulloblastoma. By utilizing the D2C7 clone, which possesses high specificity for both the overexpressed wild-type receptor and the tumor-specific vIII mutation, D2C7-CAR seeks to improve tumor clearance and prevent antigen escape mechanisms that often limit the efficacy of single-target CAR-T therapies. Preclinical studies have demonstrated robust in vitro cytotoxicity and significantly prolonged survival in orthotopic mouse models of GBM and medulloblastoma. Notably, the therapy has shown a favorable safety profile in preclinical models, with no observed cytotoxicity against EGFR-expressing human keratinocytes.

Other names

D2C7-CAR T cellsD-2C7-CAR T cellsD 2C7-CAR T cellsD2C7-targeted CAR T cellsD-2C7-targeted CAR T cellsD 2C7-targeted CAR T cells